Corvus Pharmaceuticals Statistics
Share Statistics
Corvus Pharmaceuticals has 64.26M shares outstanding. The number of shares has increased by 27.56% in one year.
| Shares Outstanding | 64.26M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 50.33M |
| Failed to Deliver (FTD) Shares | 14.22K |
| FTD / Avg. Volume | 1.82% |
Short Selling Information
The latest short interest is 2.93M, so 4.55% of the outstanding shares have been sold short.
| Short Interest | 2.93M |
| Short % of Shares Out | 4.55% |
| Short % of Float | 5.86% |
| Short Ratio (days to cover) | 3.82 |
Valuation Ratios
The PE ratio is -3.13 and the forward PE ratio is -18.1.
| PE Ratio | -3.13 |
| Forward PE | -18.1 |
| PS Ratio | 0 |
| Forward PS | 27.9 |
| PB Ratio | 2.18 |
| P/FCF Ratio | -3.53 |
| PEG Ratio | n/a |
Enterprise Valuation
Corvus Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.07 |
| Quick Ratio | 4.07 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 3.43 |
| Cash Flow / Debt | -17.42 |
| Interest Coverage | -14.73 |
Financial Efficiency
Return on equity (ROE) is -0.7% and return on capital (ROIC) is -58.24%.
| Return on Equity (ROE) | -0.7% |
| Return on Assets (ROA) | -0.59% |
| Return on Capital (ROIC) | -58.24% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -965.32K |
| Employee Count | 28 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 380.39% in the last 52 weeks. The beta is 1.04, so Corvus Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | 380.39% |
| 50-Day Moving Average | 8.05 |
| 200-Day Moving Average | 4.02 |
| Relative Strength Index (RSI) | 37.38 |
| Average Volume (20 Days) | 780.41K |
Income Statement
In the last 12 months, Corvus Pharmaceuticals had revenue of $0 and earned -$27.03M in profits. Earnings per share was $-0.56.
| Revenue | 0 |
| Gross Profit | -151.00K |
| Operating Income | -23.33M |
| Net Income | -27.03M |
| EBITDA | -26.88M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.56 |
Balance Sheet
The company has $12.62M in cash and $1.37M in debt, giving a net cash position of $11.25M.
| Cash & Cash Equivalents | 12.62M |
| Total Debt | 1.37M |
| Net Cash | 11.25M |
| Retained Earnings | -334.72M |
| Total Assets | 58.81M |
| Working Capital | -3.48M |
Cash Flow
In the last 12 months, operating cash flow was -$23.93M and capital expenditures -$34.00K, giving a free cash flow of -$23.97M.
| Operating Cash Flow | -23.93M |
| Capital Expenditures | -34.00K |
| Free Cash Flow | -23.97M |
| FCF Per Share | -0.5 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
CRVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.62% |
| FCF Yield | -5.08% |
Analyst Forecast
The average price target for CRVS is $14, which is 90.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $14 |
| Price Target Difference | 90.5% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -3.92 |
| Piotroski F-Score | 3 |